Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

View:
Post by okgonow on Mar 23, 2024 10:38am

I Hope

that with all thats happening LABS will get out and start tooting their horn. the problem as i see it now is that very few know the LABS story. I think they had the Canopy CEO on BNN on friday making his pitch as i see it when it comes to the pharma side LABS is way ahead of a company like Canopy, beeing certified in not only Canada,Germany, Australia now Braziland most importantly the FDA aproval for the USA ( I think we are still the only company that can say that). The problem again is that only a small number of people know about us. If the numbers for Q4 come in better than expected and certainly Q1 and going forward with German partial legalization (full medical) i agree as someone has said our partners will be loading up with orders for that country alone.now throw Brazil etc. in the mix and potentialy US re rating of Canabis imminentLABS SP should go thru the roof....but only if they finally start spreading the word and getting our name out there.

i for one would be very happy with $1 SP but disagree with an earlier poster saying all time high is not in the cards. that was reached on Canadian legalization  only, with all of these these new markets opening up the balance sheet will tell the story and when you can show massive income and forward projections then there is no telling where this can go. Just look at INVIDIA from $100 to $900 SP in a year and rising. your going to say ok 9 x .07 is $.63  well i think the diff here is that we have been undervalued and overlooked. with the type of potential money LABS can make 100x current SP is not out of the question if not even more.

They have to start selling themselves, not in regards to their products because i think anyone in the pharma buissness that is looking to produce canna based products probably already knows about LABS...but for us long time shareholders who have bought held and suported the company.

the time to stay quiet is over and with positive Q numbers and forward guidance there i no reason not to get the story out there

the big conundrum being is coming up with the right exit stratagie is a x3,x5,x10 good enough or do ya hold for a possibility of huge money

if anyone would like to share what that may be id be interested in listening!!!!!!!
Comment by subaru1 on Mar 23, 2024 11:48am
Very well said OKGONOW.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities